Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203
Yoko Tsukita(Tohoku University), Masakazu Ichinose(Osaki Citizen Hospital), Hisashi Tanaka(Hirosaki University), Taku Nakagawa(Saint John's Health Center), Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Masanori Fujii(Japanese Red Cross Kobe Hospital), Shoichi Kuyama(Iwakuni Medical Center), Shunichi Sugawara(Sendai Kousei Hospital), Yoshiaki Mori(Iwate Prefectural Central Hospital), Toshihiko Hino(Yamagata Prefectural Central Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Daijiro Harada(Shikoku Cancer Center)
Cited by 27
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695